Metformin, which is a widely used treatment for GDM and T2D, has been shown to be associated with an increase in SIRT1 activity (positively regulates insulin signaling) and a decrease in class II HDAC and HMT activity (24). This evidence concerns the gene INS and type 2 diabetes mellitus.